February 26, 2020
Effective April 1, 2020, the following infliximab pharmaceutical products will be recategorized as group C products instead of multi-source products. This will affect the reimbursement rate on these medications.
Code |
Drug Name |
J1745 |
REMICADE 100MG Solution Reconstituted |
Q5103 |
INFLECTRA 100MG Solution Reconstituted |
If you have additional questions, email provider inquiries or call the Provider Contract Support Unit at 800-722-3730, Option 2.